94 related articles for article (PubMed ID: 2067126)
1. An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer.
Ohtsu A; Yoshida S; Saito D; Shimada Y; Miyamoto K; Fujii T; Yoshino M; Yoshimori M
Jpn J Clin Oncol; 1991 Apr; 21(2):120-4. PubMed ID: 2067126
[TBL] [Abstract][Full Text] [Related]
2. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
[TBL] [Abstract][Full Text] [Related]
3. Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
Cazap EL; Gisselbrecht C; Smith FP; Estevez RA; Alvarez CA; Lagarde C; Hannois A; Ahmed S; Schein PS; Woolley PV
Cancer Treat Rep; 1986 Jun; 70(6):781-3. PubMed ID: 3524826
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study.
Williamson SK; Tangen CM; Maddox AM; Spiridonidis CH; Macdonald JS
Am J Clin Oncol; 1995 Dec; 18(6):484-7. PubMed ID: 8526189
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG).
Ohtsu A; Shimada Y; Yoshida S; Saito H; Seki S; Morise K; Kurihara M
Eur J Cancer; 1994; 30A(14):2091-3. PubMed ID: 7857709
[TBL] [Abstract][Full Text] [Related]
7. [Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
Mochizuki F; Tomioka K; Mizuno Y; Sato F; Yamagata T; Nagakawa Y; Kobari Y; Fujii M; Iwai S; Tanaka T
Gan To Kagaku Ryoho; 1995 Jan; 22(1):115-8. PubMed ID: 7826065
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
Baba E; Fujishima H; Kusaba H; Esaki T; Ariyama H; Kato K; Tanaka R; Mitsugi K; Shibata Y; Harada M; Nakano S
Anticancer Res; 2009 May; 29(5):1727-32. PubMed ID: 19443394
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C
Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491
[TBL] [Abstract][Full Text] [Related]
10. Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: a pilot study.
Yeh KH; Cheng AL; Chen YC; Chen BR; Lee WJ; Lin JT; Lee PH; Chang KJ; Wang CH; Wang TH
J Formos Med Assoc; 1994 Jan; 93(1):20-4. PubMed ID: 7915575
[TBL] [Abstract][Full Text] [Related]
11. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Dalla Chiesa M; Tomasello G; Buti S; Rovere RK; Brighenti M; Lazzarelli S; Donati G; Passalacqua R
Cancer Chemother Pharmacol; 2011 Jan; 67(1):41-8. PubMed ID: 20204366
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
Gan To Kagaku Ryoho; 1999 Jun; 26(7):933-8. PubMed ID: 10396320
[TBL] [Abstract][Full Text] [Related]
14. [A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP].
Ishio T; Kohnoe S; Endo K; Yamamoto M; Ikeda Y; Toh Y; Baba H; Okamura T; Kawamoto K
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1627-30. PubMed ID: 12355950
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
16. Treatment of gastric adenocarcinoma with the combination of etoposide, adriamycin and cisplatin (EAP): comparison between two schedules.
Haim N; Tsalik M; Robinson E
Oncology; 1994; 51(1):102-7. PubMed ID: 8265093
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
18. [A case of advanced gastric cancer successfully treated with TS-1/CDDP combination chemotherapy, able to maintain CR for more than two years against multiple liver metastases].
Meguro E; Kimura T; Noda Y; Matsumoto Y; Irinoda T; Hayakawa Y; Kobayashi M; Takagane A; Hioki J
Gan To Kagaku Ryoho; 2007 Feb; 34(2):249-52. PubMed ID: 17301537
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer. An Eastern Cooperative Oncology Group study.
Clark JL; Küçük O; Neuberg DS; Benson AB; Taylor SG; Pandya KJ; Mansour EG; Douglass HO; Haller DG
Am J Clin Oncol; 1995 Aug; 18(4):318-24. PubMed ID: 7625373
[TBL] [Abstract][Full Text] [Related]
20. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
